<a href="https://www.fiercebiotech.com/biotech/gilead-pays-kymera-45m-glue-preclinical-protein-degrader-burgeoning-oncology-pipeline" hreflang="en">Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline </a>
fiercebiotech.com·Apr 9, 2026
Gilead has expanded its drug pipeline by paying $45 million to acquire Kymera Therapeutics' preclinical anticancer molecular glue degrader.
For someone tracking biotech and AI drug discovery, Gilead's decision to invest $45 million in Kymera Therapeutics' preclinical molecular glue degrader highlights the growing interest and investment in novel therapeutic modalities. This move signals a potential shift towards innovative cancer treatment approaches, suggesting opportunities for further investment or collaboration in the molecular glue degrader space within the biotech sector.